KINGSTON, R.I. – June 16, 2014 – People respond differently to drugs because of variations in their genes, age, gender or the presence of diseases such as diabetes or liver disease. The latest research in this area is being presented during a conference at the University of Rhode Island College of Pharmacy.
The conference, Pharmacogenomic Interplay in Biotransformation and Pharmacokinetics, will be held Aug. 7 and 8, with an early registration deadline of July 1.
Scientists believe that someday, treatment of certain cancers or diabetes can be personalized based on an individual’s genes or other differences.
Drawing on the URI faculty’s strength in the area of drug disposition at cellular and molecular levels, the conference presenters also include scientists from universities including Harvard, Tufts, and the University of Connecticut; companies such as Pfizer, Certara and SystaMedic; and the U.S. Food and Drug Administration.
The conference is designed to serve faculty and graduate students as well as scientists in industry, biopharmaceutics and contract research organizations and senior managers seeking to understand the role of pharmacogenomics in drug disposition and toxicity; regulatory scientists who need to understand recent regulations on biopharmaceuticals and biosimilars; and pharmacists and health care providers.
Click here for more information.